Abiopharma

🔍 Primus Guy Warren (Director)

Company: LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 25,000 shares of Common Stock (Direct)
  Date: 2026-04-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 25,000.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 25,000 shares of Stock Option (right to buy) at $4.05 per share (Derivative)
  Date: 2026-04-15 | Code: D | Expires: 2030-12-24 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on December 24, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant.
• F2: The canceled Options provided for vesting 50% on the grant date, the remaining 50% vesting in equal installments of 12.5% on March 31, 2026 and on the last date of each subsequent calendar quarter thereafter until fully vested.